

TABLE 1—SUMMARY OF DATA USED IN FEE CALCULATIONS—Continued

	Actual total costs			3-Year average actual costs	3-Year total volume %	Adjusted volume costs	2021 Assessed fee
	FY 2018	FY 2019	FY 2020				
OneChicago, LLC Futures Exchange	61,276	20,425	0.13	10,648	10,648
Subtotal	607,946	744,973	658,001	670,307	100.00	670,307	546,255
National Futures Association	507,673	540,821	567,719	538,738	538,738
Total	1,115,619	1,285,794	1,225,720	1,209,044	100.00	670,307	1,084,993

Columns may not add due to rounding.

An example of how the fee is calculated for one exchange, the Chicago Board of Trade, is set forth here:

a. Actual three-year average costs = \$27,058.

b. The alternative computation is: $[(.5) (\$27,058)] + (.5) [(.33307) (\$670,307)] = \$125,158$.

c. The fee is the lesser of a or b; in this case \$27,058.

As noted above, the alternative calculation based on contracts traded is not applicable to NFA because it is not a DCM and has no contracts traded. The Commission's average annual cost for conducting oversight review of the NFA rule enforcement program during fiscal years 2018 through 2020 was \$538,738.

The fee to be paid by the NFA for the current fiscal year is \$538,738.

II. Schedule of Fees

Fees for the Commission's review of the rule enforcement programs at the registered futures associations and DCMs regulated by the Commission are as follows:

TABLE 2—SCHEDULE OF FEES

	3-Year average actual costs	3-Year total volume %	Adjusted volume costs	2021 Assessed fee
Cantor Futures Exchange, L.P	\$26,418	0.03	\$13,319	\$13,319
CBOE Futures Exchange, LLC	26,625	1.24	17,482	17,482
Chicago Board of Trade	27,058	33.31	125,158	27,058
Chicago Mercantile Exchange, Inc	293,282	42.97	290,666	290,666
Eris Exchange, LLC	11,057	0.00	5,540	5,540
ICE Futures U.S., Inc	105,620	6.59	74,885	74,885
Minneapolis Grain Exchange, Inc	13,321	0.05	6,813	6,813
Nasdaq OMX Futures Exchange, Inc	37,051	0.27	19,444	19,444
New York Mercantile Exchange/Commodity Exchange, Inc	11,825	0.08	6,180	6,180
Nodal Exchange, LLC	48,248	0.21	24,844	24,844
North American Derivatives Exchange, Inc	20,425	0.13	10,648	10,648
OneChicago, LLC Futures Exchange	49,377	15.11	75,328	49,377
Subtotal	670,307	100.00%	670,307	546,255
National Futures Association	538,738	538,738
Total	1,209,044	100.00	670,307	1,084,993

Columns may not add due to rounding.

III. Payment Method

The Debt Collection Improvement Act (DCIA) requires deposits of fees owed to the government by electronic transfer of funds. See 31 U.S.C. 3720. All payments should be made via the government payment website <https://www.pay.gov/public/form/start/105542374/>. Credit card payments are only acceptable for amounts less than or equal to \$24,999. All payments equal to or above \$25,000 can be made by electronic funds transfer. Fees collected from each self-regulatory organization shall be deposited in the Treasury of the United States as miscellaneous receipts. See 7 U.S.C 16a.

Issued in Washington, DC, on this 14th day of June, 2022, by the Commission.

Robert Sidman,

Deputy Secretary of the Commission.

[FR Doc. 2022-13141 Filed 6-16-22; 8:45 am]

BILLING CODE 6351-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 410, 414, 488, and 493

[CMS-3368-CN]

RIN 0938-AT83

Medicare Program; Accrediting Organizations—Changes of Ownership; Correction

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Final rule; correction.

SUMMARY: This document corrects technical errors that appeared in the final rule published in the **Federal Register** on April 29, 2022 entitled “Accrediting Organizations—Changes of Ownership.”

DATES: This correction is effective June 28, 2022.

FOR FURTHER INFORMATION CONTACT: Caroline Gallaher, (410) 786–8705.

SUPPLEMENTARY INFORMATION:

I. Background

In FR Doc. 2022–09102 of April 29, 2022 (87 FR 25413), there were technical errors that are identified and corrected in this correcting document. The provisions in this correction document are effective as if they had been included in the document published April 29, 2022. Accordingly, the correction is effective June 28, 2022.

II. Summary of Errors

On page 25422 in the second column, first full paragraph, and page 25423, in the second column, under Section IV, the third bulleted paragraph, we inadvertently cited § 488.5(f)(10) instead of § 488.5(a)(10). We are deleting the regulatory citation “§ 488.5(f)(10)” and replacing it with “§ 488.5(a)(10).”

On page 25423, in the second column, under Section IV, the third bulleted paragraph, we inadvertently omitted language indicating our withdrawal of the proposal to apply the terms of § 488.5(f)(10) to clinical laboratories because an already-existing regulatory provision at 42 CFR 493.575(g) addresses the same subject matter.

On page 25427, in the third column, last line, we inadvertently referred to § 488.5(f)(10) instead of § 488.5(a)(10).

We are therefore deleting the reference to paragraph “(f)(10)” and replacing it with paragraph “(a)(10).”

On page 25428, in the third full paragraph of the third column, we inadvertently retained “clinical laboratories” in 42 CFR 488.5(f)(10). Therefore, as noted above, we are deleting the reference to clinical laboratories.

III. Waiver of Proposed Rulemaking

We ordinarily publish a notice of proposed rulemaking in the **Federal Register** to provide a period for public comment before the provisions of a rule take effect in accordance with section 553(b) of the Administrative Procedure Act (APA) (5 U.S.C. 553(b)). However, we can waive this notice and comment procedure if the Secretary finds, for good cause, that the notice and comment process is impracticable, unnecessary, or contrary to the public interest, and incorporates a statement of the finding and the reasons therefore in the notice.

Section 553(d) of the APA ordinarily requires a 30-day delay in effective date of final rules after the date of their publication in the **Federal Register**.

This 30-day delay in effective date can be waived; however, if an agency finds for good cause that the delay is impracticable, unnecessary, or contrary to the public interest, and the agency incorporates a statement of the findings and its reasons in the rule issued.

We believe that this correcting document does not constitute a rule that is subject to the notice and comment or delayed effective date requirements. This document corrects an inadvertent language retention that we intended to delete. Existing regulations at § 493.575(g) set forth steps for

laboratories to follow to maintain their accreditation status if CMS approval of their Accrediting Organizations has been involuntarily terminated.

IV. Correction of Errors

■ In FR Doc. 2022–09102 of April 29, 2022 (87 FR 25413), make the following corrections:

- On page 25422 in the second column, first full paragraph, 11th line, remove “§ 488.5(f)(10)” and add in its place “§ 488.5(a)(10)”.

- On page 25423, in the second column, under Section IV, third bulleted paragraph, 9th line, remove “§ 488.5(f)(10)” and add in its place “§ 488.5(a)(10)”.

- On page 25423, in the second column, under Section IV, add the following fourth bulleted paragraph:

“Revised § 488.5(f)(10) to withdraw the reference to “clinical laboratories” because the policy for laboratories is already set out at 42 CFR 493.575(g).”.

§ 488.5 [Corrected]

■ 1. On page 25427, in third column, in § 488.5(f)(2)(iii)(D), remove “(f)(10)” and add in its place “(a)(10)”.

■ 2. On page 25428, in the third column, in § 488.5(f)(10) introductory text, remove the words “suppliers; Diabetic Self-Management Training (DSMT) entities; or clinical laboratories,” and add in their place “suppliers; or Diabetic Self-Management Training (DSMT) entities,”.

Wilma M. Robinson,

Deputy Executive Secretary to the Department, Department of Health and Human Services.

[FR Doc. 2022–13052 Filed 6–16–22; 8:45 am]

BILLING CODE 4120–01–P